Antidepressant effect of Ziprasidone in wistar albino rat by forced swimming test model

Authors

Hansraj Kumar

RAJENDRA INSTITUTE OF MEDICAL SICENCES (RIMS), Ranchi, Jharkhand, India.
Arijit Das

Junior Resident,
Department of Pharmacology,
Rajendra Institute of Medical Science, RIMS, Ranchi
Sabyasachi Mondal

Junior Resident,
Department of Pharmacology,
Rajendra Institute of Medical Science, RIMS, Ranchi
Rajiv Kumar

Associate Professor,
Department of Pharmacology,
Rajendra Institute of Medical Science, RIMS, Ranchi
U. S. P. Keshri

Associate Professor,
Department of Pharmacology,
Rajendra Institute of Medical Science, RIMS, Ranchi
Manju Gari

Professor & Head of the Department, Department of Pharmacology,
Rajendra Institute of Medical Science, RIMS, Ranchi

DOI:

https://doi.org/10.7439/ijpr.v6i10.3709

Keywords:

ayurveda, medicinal plants, herbalism, Anti-inflammatory

Abstract

Background: Major depressive disorder is a common psychiatric condition and response conventional antidepressant drugs are sometimes unpredictable. Atypical antipsychotics by virtue of their pharmacodynamic profile show potential antidepressant effect. Newer antidepressants as monotherapy or as augmenting agent for current therapy are need of the day. Ziprasidone is an atypical antidepressant drug possesses potential antidepressant activity by virtue of its 5HT1A agonistic activity and 5HT1D, 5HT2A and D2 receptors antagonistic activity. Method : Since its introduction in 1977 the forced swimming test model is still being used for evaluation of potential antidepressant molecule. 30 healthy male Wistar albino rat of 150-200 grams weight were divided in 3 groups with 10 rats in each. Group A was treated with 0.9% Normal Saline, Group B with Fluoxetine and Group C with Ziprasidone for 42 days. Forced Swimming test was done on day 0, 7, 14, 21, 28, 35 and 42 days. Result: After 42 days of treatment both fluoxetine and ziprasidone shows significant antidepressant activity. In comparison to Normal saline both the drugs shows significant antidepressant activity. There is significant deference in antidepressant activity between Fluoxetine and Ziprasidone. Antidepressant activity of Fluoxetine started to appear from day 7 with p vale of 0.000 and of Ziprasidone started to appear from 14 days with p value of 0.000. Conclusion: Ziprasidone as virtue of its diverse pharmacodynamic effect can be suitable candidate for clinical trials of MDD as monotherapy or as an augmenting agent of standard antidepressant therapy.

Downloads

Download data is not yet available.

Published

2016-11-01

How to Cite

Kumar H, Das A, Mondal S, Kumar R, Keshri USP, Gari M. . Int J of Pharmc Res [Internet]. 2016Nov.1 [cited 2020May30];6(10):316-21. Available from: https://ssjournals.net/index.php/ijpr/article/view/3709

Issue

Vol. 6 No. 10 (2016): Oct

Section

Research Articles

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
4. Author must Submit Copyright form After acceptance of Article